skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Immunoscintigraphy of human tumors transplanted in nude mice with radiolabeled anti-ras p21 monoclonal antibodies

Abstract

Anti-ras p21 monoclonal antibody (RASK-3) was used for immunoscintigraphy of human cancer cell lines in nude mice. Iodine-125-labeled RASK-3 was injected into nude mice with either human colon cancers (FCC-1 or BM-314) or lung cancer (KNS-62). Clear images were obtained in all three cancers 7 days after the injection of antibody. No localization of {sup 125}I-labeled control monoclonal antibody was observed. The ratio of tissue/blood radioactivity and % ID/g in the tumor were significantly higher than other organs by Day 8. The specific localization index examined by {sup 131}I-RASK-3 and {sup 125}I-control monoclonal antibody was also higher in the tumor than in other tissues. In the in vitro study, binding of RASK-3 to tumor cells increased significantly by treatment of cells with either lysolecithin or periodate-lysine-paraformaldehyde, which confirmed the intracellular localization of ras p21. The mechanism by which anti-ras p21 antibodies accumulate in tumor sites could be the necrotic changes in tumor cells or changes in membrane permeability of non-necrotic cells. These results provide a strong rationale for the utilization of ras p21 as a target antigen in the imaging of a variety of human cancers.

Authors:
; ; ; ; ; ; ; ; ;  [1]
  1. Nagasaki Univ. School of Medicine (Japan)
Publication Date:
OSTI Identifier:
6510894
Resource Type:
Journal Article
Journal Name:
Journal of Nuclear Medicine; (USA)
Additional Journal Information:
Journal Volume: 31:9; Journal ID: ISSN 0161-5505
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; EXPERIMENTAL NEOPLASMS; DIAGNOSIS; LARGE INTESTINE; LUNGS; MONOCLONAL ANTIBODIES; SPECIFICITY; IODINE 125; IODINE 131; MAN; MICE; RADIOIMMUNOSCINTIGRAPHY; ANIMALS; ANTIBODIES; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BODY; COUNTING TECHNIQUES; DAYS LIVING RADIOISOTOPES; DIAGNOSTIC TECHNIQUES; DIGESTIVE SYSTEM; ELECTRON CAPTURE RADIOISOTOPES; GASTROINTESTINAL TRACT; INTERMEDIATE MASS NUCLEI; INTESTINES; IODINE ISOTOPES; ISOTOPE APPLICATIONS; ISOTOPES; MAMMALS; NUCLEI; ODD-EVEN NUCLEI; ORGANS; PRIMATES; RADIOIMMUNODETECTION; RADIOISOTOPE SCANNING; RADIOISOTOPES; RESPIRATORY SYSTEM; RODENTS; SCINTISCANNING; TRACER TECHNIQUES; VERTEBRATES; 550601* - Medicine- Unsealed Radionuclides in Diagnostics

Citation Formats

Katoh, Y, Nakata, K, Kohno, K, Shima, M, Satoh, A, Kusumoto, Y, Ishii, N, Kohji, T, Shiku, H, and Nagataki, S. Immunoscintigraphy of human tumors transplanted in nude mice with radiolabeled anti-ras p21 monoclonal antibodies. United States: N. p., 1990. Web.
Katoh, Y, Nakata, K, Kohno, K, Shima, M, Satoh, A, Kusumoto, Y, Ishii, N, Kohji, T, Shiku, H, & Nagataki, S. Immunoscintigraphy of human tumors transplanted in nude mice with radiolabeled anti-ras p21 monoclonal antibodies. United States.
Katoh, Y, Nakata, K, Kohno, K, Shima, M, Satoh, A, Kusumoto, Y, Ishii, N, Kohji, T, Shiku, H, and Nagataki, S. 1990. "Immunoscintigraphy of human tumors transplanted in nude mice with radiolabeled anti-ras p21 monoclonal antibodies". United States.
@article{osti_6510894,
title = {Immunoscintigraphy of human tumors transplanted in nude mice with radiolabeled anti-ras p21 monoclonal antibodies},
author = {Katoh, Y and Nakata, K and Kohno, K and Shima, M and Satoh, A and Kusumoto, Y and Ishii, N and Kohji, T and Shiku, H and Nagataki, S},
abstractNote = {Anti-ras p21 monoclonal antibody (RASK-3) was used for immunoscintigraphy of human cancer cell lines in nude mice. Iodine-125-labeled RASK-3 was injected into nude mice with either human colon cancers (FCC-1 or BM-314) or lung cancer (KNS-62). Clear images were obtained in all three cancers 7 days after the injection of antibody. No localization of {sup 125}I-labeled control monoclonal antibody was observed. The ratio of tissue/blood radioactivity and % ID/g in the tumor were significantly higher than other organs by Day 8. The specific localization index examined by {sup 131}I-RASK-3 and {sup 125}I-control monoclonal antibody was also higher in the tumor than in other tissues. In the in vitro study, binding of RASK-3 to tumor cells increased significantly by treatment of cells with either lysolecithin or periodate-lysine-paraformaldehyde, which confirmed the intracellular localization of ras p21. The mechanism by which anti-ras p21 antibodies accumulate in tumor sites could be the necrotic changes in tumor cells or changes in membrane permeability of non-necrotic cells. These results provide a strong rationale for the utilization of ras p21 as a target antigen in the imaging of a variety of human cancers.},
doi = {},
url = {https://www.osti.gov/biblio/6510894}, journal = {Journal of Nuclear Medicine; (USA)},
issn = {0161-5505},
number = ,
volume = 31:9,
place = {United States},
year = {Sat Sep 01 00:00:00 EDT 1990},
month = {Sat Sep 01 00:00:00 EDT 1990}
}